Macular Edema - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2016, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 2, 9, 1 and 1 respectively.Macular Edema.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Macular Edema Overview 7
Therapeutics Development 8
Pipeline Products for Macular Edema - Overview 8
Macular Edema - Therapeutics under Development by Companies 9
Macular Edema - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Macular Edema - Products under Development by Companies 13
Macular Edema - Companies Involved in Therapeutics Development 14
ActiveSite Pharmaceuticals, Inc. 14
Ampio Pharmaceuticals, Inc. 15
Chong Kun Dang Pharmaceutical Corp. 16
Clearside BioMedical, Inc. 17
Coherus BioSciences, Inc. 18
Mabion SA 19
Pfizer Inc. 20
Precision Ocular Ltd 21
Promedior, Inc. 22
Taiwan Liposome Company, Ltd. 23
Valeant Pharmaceuticals International, Inc. 24
Xbrane Biopharma AB 25
Macular Edema - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(aflibercept + triamcinolone acetonide) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ACX-107 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ASPPDC-020 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
BLO-021 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
celecoxib - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
danazol - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
dexamethasone sodium phosphate SR - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
HO-10 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
PRM-167 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ranibizumab biosimilar - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ranibizumab biosimilar - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ranibizumab biosimilar - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
ranibizumab biosimilar - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Macular Edema - Dormant Projects 56
Macular Edema - Discontinued Products 57
Macular Edema - Product Development Milestones 58
Featured News & Press Releases 58
Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting 58
Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion 58
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 59
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 60
Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion 60

Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Macular Edema, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Comparative Analysis by Unknown Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2016 14
Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 15
Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 16
Macular Edema - Pipeline by Clearside BioMedical, Inc., H2 2016 17
Macular Edema - Pipeline by Coherus BioSciences, Inc., H2 2016 18
Macular Edema - Pipeline by Mabion SA, H2 2016 19
Macular Edema - Pipeline by Pfizer Inc., H2 2016 20
Macular Edema - Pipeline by Precision Ocular Ltd, H2 2016 21
Macular Edema - Pipeline by Promedior, Inc., H2 2016 22
Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 23
Macular Edema - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 24
Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Macular Edema - Dormant Projects, H2 2016 56
Macular Edema - Discontinued Products, H2 2016 57